AquaBounty Technologies, Inc. (LON:ABTU) Files An 8-K Other Events

AquaBounty Technologies, Inc. (LON:ABTU) Files An 8-K Other Events

Story continues below

Item 8.01 Other Events.

On April 7, 2017, AquaBounty Technologies, Inc. (the Company)
issued a press release regarding its having made an application
to the London Stock Exchange plc (the LSE) to cancel the
admission to trading of the Companys shares on AIM, a market of
the LSE, and its decision to terminate its UK domestic depositary
interest facility, each subject to approval by the Companys
shareholders at its Annual General Meeting to be held on 23 May
2017. A copy of the press release is furnished herewith as
Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release issued by AquaBounty Technologies, Inc.
on April 7, 2017, furnished herewith.


About AquaBounty Technologies, Inc. (LON:ABTU)

AquaBounty Technologies, Inc. is a biotechnology company engaged in research, development and commercialization of the commercial viability of a group of proteins, antifreeze proteins (AFPs). The Company focuses on the managing aquaculture productivity. It offers AquAdvantage Salmon (AAS), which can be grown in contained, land-based facilities. It offers AquAdvantage Salmon for land-based facilities that can be built closer to consumers to manage the need for air freight shipping and transportation. The Company’s subsidiaries include AquaBounty Canada, Inc., which operates a commercial biotechnology laboratory that conducts research and development programs related to the Company’s technologies; AquaBounty Panama, S. de R.L.; AquaBounty Farms, Inc., and AquaBounty Brasil Participacoes Ltda., which conducts commercial trials of the Company’s AquAdvantage Salmon.

AquaBounty Technologies, Inc. (LON:ABTU) Recent Trading Information

AquaBounty Technologies, Inc. (LON:ABTU) closed its last trading session down -12.50 at 975.00 with 0 shares trading hands.

An ad to help with our costs